A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

Giesen, Nicola; Chatterjee, Manik; Scheid, Christof; Poos, Alexandra M.; Besemer, Britta; Miah, Kaya; Benner, Axel; Becker, Nicole; Moehler, Thomas; Metzler, Ivana; Khandanpour, Cyrus; Seidel-Glaetzer, Andrea; Trautmann-Grill, Karolin; Kortuem, K. Martin; Mueller-Tidow, Carsten; Mechtersheimer, Gunhild; Goeppert, Benjamin; Stenzinger, Albrecht; Weinhold, Niels; Goldschmidt, Hartmut; Weisel, Katja; Raab, Marc S.

dc.contributor.author	Besemer, Britta
dc.date.accessioned	2023-07-24T05:57:42Z
dc.date.available	2023-07-24T05:57:42Z
dc.date.issued	2023
dc.identifier.issn	0006-4971
dc.identifier.uri	http://hdl.handle.net/10900/143585
dc.language.iso	en	de_DE
dc.publisher	Amer Soc Hematology	de_DE
dc.relation.uri	http://dx.doi.org/10.1182/blood.2022017789	de_DE
dc.subject.ddc	610	de_DE
dc.title	A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230619000000_00459
utue.publikation.seiten	1685-1690	de_DE
utue.personen.roh	Giesen, Nicola
utue.personen.roh	Chatterjee, Manik
utue.personen.roh	Scheid, Christof
utue.personen.roh	Poos, Alexandra M.
utue.personen.roh	Besemer, Britta
utue.personen.roh	Miah, Kaya
utue.personen.roh	Benner, Axel
utue.personen.roh	Becker, Nicole
utue.personen.roh	Moehler, Thomas
utue.personen.roh	Metzler, Ivana
utue.personen.roh	Khandanpour, Cyrus
utue.personen.roh	Seidel-Glaetzer, Andrea
utue.personen.roh	Trautmann-Grill, Karolin
utue.personen.roh	Kortuem, K. Martin
utue.personen.roh	Mueller-Tidow, Carsten
utue.personen.roh	Mechtersheimer, Gunhild
utue.personen.roh	Goeppert, Benjamin
utue.personen.roh	Stenzinger, Albrecht
utue.personen.roh	Weinhold, Niels
utue.personen.roh	Goldschmidt, Hartmut
utue.personen.roh	Weisel, Katja
utue.personen.roh	Raab, Marc S.
dcterms.isPartOf.ZSTitelID	Blood	de_DE
dcterms.isPartOf.ZS-Issue	14	de_DE
dcterms.isPartOf.ZS-Volume	141	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE